Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
BMC Cancer|August 6, 2024
Setting the international research agenda for sarcomas with patients and carers: results of phase II of the Sarcoma Patient Advocacy Global Network (SPAGN) priority setting partnershipE Roets, K Schuster, S Bickley, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 31, 2024
Interleukin-6 in relation to early recurrence in primary, localized soft tissue sarcoma: An addition for existing risk classification systems?P van der Laan, W T A van der Graaf, D van den Broek, et al.
The Pharmacogenomics Journal|January 25, 2017
Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinibJ S L Kloth, M C Verboom, J J Swen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 12, 2023
Elevated preoperative serum interleukin-6 level is predictive for worse postoperative outcome after soft tissue sarcoma surgeryP van der Laan, W T A van der Graaf, S J M Reijers, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 13, 2018
Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registryP A Boonstra, N Steeghs, S Farag, et al.
ESMO Open|June 12, 2025
The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcomaP van der Laan, W J van Houdt, H van Boven, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 26, 2025
Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC studyE Roets, E Younger, R L Jones, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2021
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitorsR B Verheijen, T T van Duijl, M M van den Heuvel, et al.
Cancer Chemotherapy and Pharmacology|March 22, 2023
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patientsStefanie L Groenland, J M Janssen, C M Nijenhuis, et al.
ESMO Open|April 5, 2025
Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudyA C Chiang, M E Olmedo Garcia, J W Carlisle, et al.
Pageof 5